1. Low Molecular Weight Mannogalactofucans Derived from Undaria pinnatifida Induce Apoptotic Death of Human Prostate Cancer Cells In Vitro and In Vivo
- Author
-
Peter Capek, Sarang Cho, Jisun Lee, Seul Ki Lee, Yong Il Park, Woo Jung Kim, Andriy Synytsya, Chang Won Lee, and Ji Won Choi
- Subjects
0301 basic medicine ,Male ,Programmed cell death ,Poly ADP ribose polymerase ,Apoptosis ,Undaria ,Applied Microbiology and Biotechnology ,03 medical and health sciences ,Prostate cancer ,Mice ,0302 clinical medicine ,In vivo ,Polysaccharides ,medicine ,Animals ,Humans ,RNA, Messenger ,Protein kinase B ,Caspase ,beta Catenin ,Membrane Potential, Mitochondrial ,Glycogen Synthase Kinase 3 beta ,biology ,Prostatic Neoplasms ,Cell Cycle Checkpoints ,medicine.disease ,Molecular biology ,In vitro ,Molecular Weight ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,biology.protein - Abstract
Low molecular weight mannogalactofucans (LMMGFs) prepared by enzymatic degradation of high molecular weight Undaria galactofucan (MF) were evaluated for their anti-cancer effects against human prostate cancer. Correlation NMR and linkage analyses confirmed that LMMGFs consist mainly of α-fucose and β-galactose units: α-fucose units are 1,3-linked; β-galactose units are terminal, 1,3- and/or 1,6-linked; both sugars are partially sulphated, fucose at positions O-2 and/or O-4 and galactose at O-3. Mannose residue, as a minor sugar, presents as the 1,4-linked terminal units. LMMGFs more significantly induced cell cycle arrest at the G0/G1 phase and cell death via suppression of the Akt/GSK-3β/β-catenin pathway than MF in human PC-3 prostate cancer cells. LMMGFs upregulated mRNA expression of death receptor-5 (DR-5), the ratio of Bax to Bcl-2, the cleavage of caspases and PARP, the depolarisation of mitochondrial membrane potential, and ROS generation. LMMGFs (200-400 mg/kg) effectively reduced both tumour volume and size in a xenografted mouse model. These results demonstrated that LMMGFs attenuate the growth of human prostate cancer cells both in vitro and in vivo, suggesting that LMMGFs can be used as a potent functional ingredient in health-beneficial foods or as a therapeutic agent to prevent or treat androgen-independent human prostate cancer. Graphical Abstract.
- Published
- 2018